(Q46981409)

27 December 2017

title

Development of an in vivo rat screen model to predict pharmacokinetic interactions of CYP3A4 substrates (English)

1 reference

27 December 2017

1 reference

S V Mandlekar

1

1 reference

27 December 2017

A V Rose

2

1 reference

27 December 2017

G Cornelius

3

1 reference

27 December 2017

B Sleczka

4

1 reference

27 December 2017

C Caporuscio

5

1 reference

27 December 2017

J Wang

6

1 reference

27 December 2017

P H Marathe

7

1 reference

27 December 2017

language of work or name

English

0 references

publication date

1 September 2007

1 reference

27 December 2017

published in

Xenobiotica

1 reference

27 December 2017

volume

37

1 reference

27 December 2017

issue

9

1 reference

27 December 2017

page(s)

923-942

1 reference

27 December 2017

Rofecoxib is a potent inhibitor of cytochrome P450 1A2: studies with tizanidine and caffeine in healthy subjects

cites work

1 reference

https://api.crossref.org/works/10.1080%2F00498250701570269

Current methodologies used for evaluation of intestinal permeability and absorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250701570269

Utility of 96 well Caco-2 cell system for increased throughput of P-gp screening in drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250701570269

Cerebral uptake of mefloquine enantiomers with and without the P-gp inhibitor elacridar (GF1210918) in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250701570269

The Conduct of In Vitro and In Vivo Drug-Drug Interaction Studies: A PhRMA Perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250701570269

Pharmacokinetic factors in the adverse cardiovascular effects of antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250701570269

In vivo modulation of intestinal CYP3A metabolism by P-glycoprotein: studies using the rat single-pass intestinal perfusion model

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250701570269

New technologies and screening strategies for hepatotoxicity: use of in vitro models

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250701570269

Approach to the prediction of the contribution of major cytochrome P450 enzymes to drug metabolism in the early drug-discovery stage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250701570269

The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250701570269

Cytochrome P-450 3A4: regulation and role in drug metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250701570269

Inhibitory effects of psychotropic drugs on mexiletine metabolism in human liver microsomes: prediction of in vivo drug interactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250701570269

Transporters and drug therapy: implications for drug disposition and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250701570269

Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250701570269

Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250701570269

Factors influencing regional differences in intestinal absorption of UK-343,664 in rat: possible role in dose-dependent pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250701570269

In vivo effects of cyclosporin A and ketoconazole on the pharmacokinetics of representative substrates for P-glycoprotein and cytochrome P450 (CYP) 3A in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250701570269

Quantitative prediction of in vivo drug-drug interactions from in vitro data based on physiological pharmacokinetics: use of maximum unbound concentration of inhibitor at the inlet to the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250701570269

Assessment of the hepatic and intestinal first-pass metabolism of midazolam in a CYP3A drug-drug interaction model rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250701570269

High-throughput screening of inhibitory potential of nine cytochrome P450 enzymes in vitro using liquid chromatography/tandem mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250701570269

Selectivities of human cytochrome P450 inhibitors toward rat P450 isoforms: study with cDNA-expressed systems of the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250701570269

Pharmacokinetics and electroencephalographic effects of ketoconazole in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250701570269

In vitro, pharmacokinetic, and pharmacodynamic interactions of ketoconazole and midazolam in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250701570269

Effect of multiple dosing of ketoconazole on pharmacokinetics of midazolam, a cytochrome P-450 3A substrate in beagle dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250701570269

Effect of oral ketoconazole on first-pass effect of nifedipine after oral administration in dogs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250701570269

Pharmacokinetic and Pharmacodynamic Interactions of Oral Midazolam with Ketoconazole, Fluoxetine, Fluvoxamine, and Nefazodone

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250701570269

In vivo animal models for investigating potential CYP3A- and Pgp-mediated drug-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250701570269

In vitro cytochrome P450 inhibition data and the prediction of drug-drug interactions: qualitative relationships, quantitative predictions, and the rank-order approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250701570269

Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250701570269

Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250701570269

Evaluation of human liver slices and reporter gene assays as systems for predicting the cytochrome p450 induction potential of drugs in vivo in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250701570269

Torsade de pointes induced by cisapride/clarithromycin interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250701570269

Effects of ketoconazole on digoxin absorption and disposition in rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250701570269

Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug inter

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250701570269

Progress in understanding the structure-activity relationships of P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250701570269

Diclofenac hydroxylation in monkeys: efficiency, regioselectivity, and response to inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250701570269

In vitro and in vivo drug interactions involving human CYP3A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250701570269

Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250701570269

Effects of the antifungal agents on oxidative drug metabolism: clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250701570269

Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250701570269

Interaction of common azole antifungals with P glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250701570269

Development of an in vivo preclinical screen model to estimate absorption and first-pass hepatic extraction of xenobiotics. II. Use of ketoconazole to identify P-glycoprotein/CYP3A-limited bioavailability in the monkey

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250701570269

Potentially Significant Drug Interactions of Class III Antiarrhythmic Drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250701570269

Interaction of cytochrome P450 3A inhibitors with P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250701570269

The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250701570269

Reduction of site-specific CYP3A-mediated metabolism for dual angiotensin and endothelin receptor antagonists in various in vitro systems and in cynomolgus monkeys.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250701570269

10.1080/00498250701570269

21 January 2018

Identifiers

DOI

1 reference

27 December 2017

1 reference

27 December 2017